CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The two plots are located in the heart of Gurugram close to Sectors 53 on the Golf Course Road and Sector 56 just minutes away from the other location
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Subscribe To Our Newsletter & Stay Updated
